Search
Search Results
##search.searchResults.foundPlural##
-
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3580PDF: 2508HTML: 1496 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4292PDF: 3534HTML: 219 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2892PDF: 1242HTML: 2717Figure 1: 179 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2282PDF: 1629HTML: 274 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2220PDF: 2053HTML: 196 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9140PDF: 6091HTML: 87969Fig.1b: 191Fig.1c: 197Fig.2a: 184Fig.2b: 181Fig.4: 194Fig.2c: 190Fig.3: 188Tab.1: 236Tab.2: 214Tab.3: 195Tab.4: 229Fig1a: 192 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2315PDF: 1339HTML: 17093Bassan Fig.1: 146Bassan Fig.2: 159Bassan Fig.4: 142Fig.3: 196 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4129PDF: 1951HTML: 5325Table 1: 200 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1419PDF: 823HTML: 3124 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4351PDF: 1519HTML: 1554Untitled: 238 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3402PDF: 1292HTML: 2230Fi.1 Gritti.Rambaldi: 209 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3221PDF: 783HTML: 2967Figure 1a and 1b: 153Figure 2: 163Figure 3: 181Figure 4: 164Figure 5: 167Tables 1-5: 156 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3690PDF: 1616HTML: 80 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3791PDF: 1598HTML: 499Figures . Eliassian: 229 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1656PDF: 1104HTML: 127 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
1857PDF: 783HTML: 528 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2634PDF: 1627HTML: 2373Table1: 193 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1307PDF: 607HTML: 3103 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1261PDF: 477HTML: 18611Figure 1: 174Figure 2: 154Figure 3: 171Figure 4: 210Figure 5: 182 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4835PDF: 1795HTML: 2723Untitled: 226 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2397PDF: 1006HTML: 1652Fig 1: 190Tab I: 217Cover Letter: 208 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1300PDF: 500HTML: 205 -
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1185PDF: 606HTML: 6801 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1562PDF: 915HTML: 1967Figure: 174Tables: 190ALL revision 1: 198response to reviewer: 184 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1345PDF: 1238HTML: 460 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1601PDF: 621HTML: 209 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2057PDF: 843HTML: 259 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1413PDF: 1325HTML: 101







